Etiology Assessment and Decision Pathway Before Choosing an Overseas IVF Hospital for Recurrent Implantation Failure

Visual title (not H1, for display only)

In reproductive clinics, patients with recurrent implantation failure (RIF) are the group most in need of individualized decision-making. When a patient with a history of three or more failed transfers comes to me, my first task is not to immediately recommend a specific overseas hospital, but to conduct a systematic investigation into the causes. Only by identifying the reasons for failure can we determine whether overseas treatment can address the core issue and which type of hospital and technology offers the best match. This decision pathway directly impacts the direction and cost of subsequent treatment.

Key Tests That Must Be Clarified for Recurrent Implantation Failure

Before considering changing hospitals or going abroad, the following test results form the basis of evaluation. Missing any one of them could lead to decision-making errors.

It is recommended to complete the above tests before deciding on overseas treatment. If these tests have been done domestically with clear results, they can directly serve as a basis for hospital selection. If not yet completed, it is not advisable to blindly start an overseas cycle.

Etiological Stratification of Recurrent Implantation Failure

From an etiological perspective, RIF can be categorized into three levels:

• Embryo Factors (highest proportion, about 50-60%): Chromosomal aneuploidy, mosaicism, mitochondrial DNA abnormalities. This can be significantly reduced through PGT-A.
• Uterine and Endometrial Factors (about 30-40%): Includes uterine anatomical abnormalities (polyps, adhesions, adenomyosis), chronic endometritis, displaced window of implantation, and endometrial microenvironment imbalance.
• Maternal Systemic Factors (about 10-20%): Immune dysregulation, hypercoagulability, endocrine disorders (thyroid, blood glucose, vitamin D deficiency, etc.).

Different causes correspond to different solutions. For example, if the main problem is embryonic aneuploidy, choosing an overseas center with extensive experience in embryo culture and PGT technology is meaningful. If the issue lies in the uterine environment, priority should be given to evaluating whether the overseas hospital has a comprehensive process for hysteroscopy and endometrial preparation.

Easily Overlooked Details: Timeliness of Tests and Complete Records

In clinical practice, I find that patients often miss the following details when preparing for overseas treatment:

• Incomplete records of previous transfers: Missing embryo photos, grading criteria, day of blastocyst culture, and transfer procedure notes. When overseas hospitals evaluate new patients, this information is far more important than verbal descriptions.
• Timeliness of AMH and Antral Follicle Count (AFC): AMH levels can fluctuate significantly within 6 months, especially after ovarian stimulation or surgery. It should be rechecked before going abroad to avoid a mismatch between the medication plan and the actual condition.
• Chromosome reports and genetic counseling: If either partner or the embryo has a chromosomal abnormality (including balanced translocation, inversion, etc.), a detailed genetic counseling report should be obtained in advance. Some overseas countries (e.g., the US) have more mature experience with PGT-SR (structural rearrangement screening), but complete genetic evidence is required.
• Passport and visa validity: An overseas IVF cycle typically requires a stay of 14-21 days, and some cases may require multiple trips. A passport validity of less than 6 months may affect visa approval; it is advisable to check in advance.

Four Common Misconceptions When Choosing an Overseas Hospital

• Misconception 1: Only looking at the "success rate" number. The "live birth rate" published by overseas hospitals is usually for a specific population (e.g., age <35, first IVF attempt) and differs greatly from the actual situation of RIF patients. Request subgroup data for similar age and number of previous transfers.
• Misconception 2: Believing PGT can solve everything. PGT-A can only screen for embryos with a normal number of chromosomes; it cannot detect gene mutations, imprinting defects, or mitochondrial diseases. For RIF, PGT is an important tool but not a magic bullet.
• Misconception 3: Ignoring laboratory accreditation standards. The accreditation system for overseas embryo laboratories (e.g., CAP, CLIA, JCI) directly impacts culture quality and embryo stability. Be cautious of laboratories without international accreditation, no matter how advanced their claims.
• Misconception 4: Over-reliance on "comprehensive immune" treatment. Some overseas centers recommend extensive immune testing and immunosuppressive therapy, but some of these interventions lack high-quality evidence. Before adopting them, ask for supporting peer-reviewed literature.

Key Differences in RIF Diagnosis and Treatment Across Countries

Choosing an overseas hospital is essentially a trade-off between technology availability, legal frameworks, and cost structures. The following table summarizes the core differences in major regions:

RIF patients should choose a region based on the weight of their own etiology. For example, if the main issue is embryonic aneuploidy and advanced age, the US has an advantage in PGT experience and laboratory stability. If the problem is more related to endometrial receptivity and the budget is limited, some centers in Thailand or Europe can also provide ERA and hysteroscopy services.

How to Assess the True Level of an Overseas Hospital

Within the same country, the quality of diagnosis and treatment can vary greatly between hospitals. The following indicators are more reliable than advertising:

• Embryologist experience: Ask if the laboratory has dedicated embryologists for ICSI and blastocyst culture, as well as the number of cycles and blastocyst formation rate handled annually.
• Multidisciplinary consultation mechanism: For RIF patients, an ideal hospital should have a process where reproductive doctors, embryologists, immunologists, and genetic counselors discuss cases together, rather than decisions being made by a single doctor.
• Personalized transfer strategy: Is ERA testing routinely offered and transfer timing adjusted based on results? Are stratified treatment protocols used for patients with repeated implantation failure (e.g., treating endometritis first, then considering transfer)?
• Transparent data disclosure: Is the hospital willing to provide live birth rates broken down by age, number of transfers, and etiology? Be wary of institutions that refuse to provide detailed data.

How Reproductive Doctors View Overseas Treatment Decisions

As a clinician, I advise RIF patients to conduct a systematic "failure analysis review" domestically before considering overseas treatment. This review should include:

• Reviewing embryo grading, culture days, and transfer procedure records from all previous cycles.
• Completing the key tests mentioned above (PGT-A, ERA, hysteroscopy, immune screening).
• Identifying any treatable causes (e.g., endometritis, displaced window of implantation, thrombophilia).

If the review shows that the necessary technology is already available domestically (e.g., ERA testing and hysteroscopy equipment), adjusting the treatment plan at home is often a more efficient choice. Overseas hospitals only offer irreplaceable value when domestic technology cannot cover the specific need (e.g., specific PGT techniques, egg donation policy restrictions, or lack of targeted immunomodulation experience).

Most Common Questions from Patients

• Q: I've had three recurrent implantation failures. Should I go directly to the US for PGT?
  A: If the embryos transferred previously have never undergone PGT and the woman is ≥37 years old, the probability of embryonic aneuploidy is high, and PGT offers clear benefits. However, the prerequisite is that ovarian function allows for obtaining a sufficient number of eggs (usually at least 3-5 blastocysts for screening).
• Q: How far in advance should I prepare for overseas IVF?
  A: From the start of document preparation to completing a cycle, it usually takes 3-6 months. This includes: completing domestic tests (1-2 months), hospital selection and communication (2-4 weeks), visa processing (2-6 weeks), and starting medication for the menstrual cycle (about 2 weeks). It is recommended to start planning at least 4 months in advance.
• Q: If overseas IVF fails, can I continue treatment back home?
  A: Yes. After the overseas cycle, bring back all embryo culture records, genetic screening reports, and transfer summaries. Domestic doctors can use this information to formulate a subsequent plan, avoiding repeated tests.
• Q: Can I still do overseas IVF if my AMH is very low?
  A: Low AMH doesn't mean it's impossible, but the expected number of eggs retrieved needs to be assessed. If AMH <0.5 ng/mL, the number of eggs retrieved per cycle may be less than 3, significantly reducing the feasibility and cost-effectiveness of PGT. Some overseas centers (e.g., in Japan) offer specific mild stimulation protocols for low AMH, which you can inquire about.
• Q: Do overseas hospitals guarantee success?
  A: No reputable hospital can guarantee "success." RIF is a complex issue involving multiple factors like embryos, uterus, and immunity. If an institution promises a success rate, it is best to exclude them directly.

Decision Adjustments for Special Situations

For the following situations, the weight of the decision for overseas treatment changes:

• Advanced age (≥42) combined with RIF: It is recommended to prioritize evaluating the option of egg donation. Some overseas countries (e.g., US, Spain) have abundant egg donation resources with strict donor screening processes. If using own eggs is insisted upon, be prepared for the possibility that no embryos may be available for transfer after PGT screening.
• Recurrent implantation failure combined with recurrent miscarriage: Requires simultaneous investigation of both partners' karyotypes, embryonic chromosomal abnormality patterns, and maternal immune factors. Overseas hospitals' genetic counseling and immune diagnostic systems may offer a more comprehensive evaluation.
• Families with legal or ethical restrictions: For example, if sex selection is needed, or preimplantation genetic diagnosis (PGT-M) is required but not available domestically, overseas treatment may be the only option. In this case, prioritize countries where the law explicitly allows it.